Mizuho Cuts Abbott Laboratories (NYSE:ABT) Price Target to $115.00

Abbott Laboratories (NYSE:ABT) had its target price decreased by analysts at Mizuho from $125.00 to $115.00 in a report issued on Friday,MarketScreener reports. The brokerage presently has a “neutral” rating on the healthcare product maker’s stock. Mizuho’s price target indicates a potential upside of 20.76% from the company’s previous close.

Several other equities analysts have also weighed in on ABT. Oppenheimer cut their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday. Barclays increased their price target on Abbott Laboratories from $142.00 to $144.00 and gave the stock an “overweight” rating in a report on Wednesday, April 8th. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Stifel Nicolaus cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Citigroup dropped their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $121.00.

Abbott Laboratories Stock Down 0.3%

Shares of ABT stock opened at $95.23 on Friday. The stock’s 50 day simple moving average is $108.17 and its 200 day simple moving average is $119.01. Abbott Laboratories has a twelve month low of $93.92 and a twelve month high of $139.06. The company has a market capitalization of $165.85 billion, a price-to-earnings ratio of 25.57, a PEG ratio of 1.62 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the prior year, the business earned $1.09 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. Insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently modified their holdings of ABT. Charles Schwab Trust Co boosted its holdings in shares of Abbott Laboratories by 109.8% in the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new stake in Abbott Laboratories in the third quarter worth about $185,640,000. Asset Management One Co. Ltd. boosted its stake in Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after acquiring an additional 19,966 shares during the last quarter. Nordea Investment Management AB grew its position in shares of Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares during the period. Finally, AE Wealth Management LLC increased its stake in shares of Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 beat on both EPS ($1.15 vs. $1.14 est.) and revenue ($11.16B vs. $10.99B), driven by medical devices and the newly acquired cancer diagnostics business — confirms underlying growth momentum. Reuters: Abbott first-quarter results beat
• Positive Sentiment: BTIG reaffirmed a Buy and set a $131 price target (≈+38% upside vs. current price), signaling some analysts view the acquisition and growth trajectory as accretive over time. TickerReport: BTIG Reaffirms Buy
• Neutral Sentiment: Abbott officially updated FY2026 guidance to $5.38–$5.58 (includes ~$0.20 dilution from Exact Sciences) and Q2 guidance to $1.25–$1.31, which is below prior consensus — investors must weigh near-term EPS hit vs. long-term oncology exposure. PR Newswire: Abbott Reports Q1, Updates Guidance
• Neutral Sentiment: Analyst coverage remains generally bullish (Buy ratings from multiple firms and mid-$120s PTs from some outlets like 24/7 Wall St.), keeping a positive baseline for longer-term holders. 24/7 Wall St.: ABT price prediction
• Negative Sentiment: Management’s lowered guidance and the ~$0.20 EPS dilution tied to the Exact Sciences buyout spurred selling pressure; margin compression and a weak nutrition segment were flagged on the call. WSJ: Abbott cuts outlook
• Negative Sentiment: Several firms trimmed price targets after the print—Bank of America and Stifel lowered PTs (to $120) even while keeping Buy ratings, reflecting reduced near-term upside expectations. Benzinga: Analyst price target changes
• Negative Sentiment: Shares reacted negatively after the print as investors prioritized the guidance cut and merger dilution over the modest beat; short-term volatility and ETF flows were noted by several outlets. Motley Fool: Why ABT tumbled

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.